Deltex Medical Group PLC
F:DX9

Watchlist Manager
Deltex Medical Group PLC Logo
Deltex Medical Group PLC
F:DX9
Watchlist
Price: 0.007 EUR 16.67%
Market Cap: €3.7m

Intrinsic Value

DX9 price has not been updated for more than 4 years. This may indicate that the stock has been delisted.
DX9 doesn't have a meaningful market cap.

The intrinsic value for Deltex Medical Group PLC (DX9) under the Base Case is 0.0004 EUR. Compared with the current market price of 0.007 EUR, the stock appears Overvalued by 94% .

Intrinsic value calculated using DCF
€0.0004

Do our valuations actually work? See backtest results .

DX9 Intrinsic Value
0.0004
Overvaluation 94%
Intrinsic Value
Price €0.007

Valuation context is not available yet

There is not enough comparable price and intrinsic value history for DX9.

Monitor DX9
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value
Get notified when the price drops into your buy zone
Current Price €0.01
Intrinsic Value €0
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Ask AI Assistant
What other research platforms think about DX9?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is DX9 valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Deltex Medical Group PLC.

Explain Valuation
Alternatives to DX9

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one DX9 stock?

The intrinsic value for Deltex Medical Group PLC (DX9) under the Base Case is 0.0004 EUR.

Is DX9 stock undervalued or overvalued?

Compared with the current market price of 0.007 EUR, the stock appears Overvalued by 94% .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett